Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients - Episode 4
The Evolving Landscape for Atopic Dermatitis Treatment
Panelists discuss how the approval of dupilumab and subsequent biologics for moderate to severe atopic dermatitis has fundamentally transformed the treatment landscape by providing targeted, effective options with favorable safety profiles that address underlying disease pathways, shifting from symptomatic management toward long-term disease control, raising expectations for treatment outcomes, reducing reliance on systemic immunosuppressants, enabling personalized therapy based on specific inflammatory pathways, and establishing new standards for efficacy that emphasize not just skin clearance but also rapid itch relief and quality-of-life improvement.
Video content above is prompted by the following:
- Since the approval of dupilumab, how has the availability of biologics for the treatment of moderate to severe disease in recent years reshaped the treatment paradigm for atopic dermatitis?
